APA (7th ed.) Citation

Kehmann, L., Berres, M., Gonzalez-Carmona, M., Modest, D. P., Mohr, R., Wree, A., . . . Roderburg, C. (2023). Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC). BMC Cancer, 23(1), 1. https://doi.org/10.1186/s12885-023-10972-6

Chicago Style (17th ed.) Citation

Kehmann, Linde, et al. "Study Protocol of an Open-label, Single Arm Phase II Trial Investigating the Efficacy and Safety of Trifluridine/Tipiracil Combined with Irinotecan as a Second Line Therapy in Patients with Cholangiocarcinoma (TRITICC)." BMC Cancer 23, no. 1 (2023): 1. https://doi.org/10.1186/s12885-023-10972-6.

MLA (9th ed.) Citation

Kehmann, Linde, et al. "Study Protocol of an Open-label, Single Arm Phase II Trial Investigating the Efficacy and Safety of Trifluridine/Tipiracil Combined with Irinotecan as a Second Line Therapy in Patients with Cholangiocarcinoma (TRITICC)." BMC Cancer, vol. 23, no. 1, 2023, p. 1, https://doi.org/10.1186/s12885-023-10972-6.